(Q37523185)

20 August 2017

1 reference

title

Treatment of Alport syndrome: beyond animal models (English)

1 reference

20 August 2017

1 reference

Oliver Gross

1

1 reference

20 August 2017

Clifford E Kashtan

series ordinal

2

1 reference

20 August 2017

language of work or name

English

0 references

publication date

17 June 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

76

1 reference

20 August 2017

issue

6

1 reference

20 August 2017

page(s)

599-603

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2009.223

20 August 2017

exact match

0 references

cites work

Alport's syndrome, Goodpasture's syndrome, and type IV collagen.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

[From the molecular genetics of Alport's syndrome to principles of organo-protection in chronic renal diseases]

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Novel COL4A5, COL4A4, and COL4A3 mutations in Alport syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Choosing a mouse model to study the molecular pathobiology of Alport glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Renal allograft survival according to primary diagnosis: a report of the North American Pediatric Renal Transplant Cooperative Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Stem cell therapy for Alport syndrome: the hope beyond the hype

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

In hereditary nephritis angiotensin-converting enzyme inhibition decreases proteinuria and may slow the rate of progression

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Enalapril in paediatric patients with Alport syndrome: 2 years' experience

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Enalapril in children with Alport syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

The effect of aldosterone blockade in patients with Alport syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Cyclosporine a slows the progressive renal disease of alport syndrome (X-linked hereditary nephritis): results from a canine model

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Long-term effects of cyclosporine A in Alport's syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Cyclosporin therapy in patients with Alport syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Animal models of Alport syndrome: advancing the prospects for effective human gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Irradiation prolongs survival of Alport mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

X chromosome inactivation patterns in normal and X-linked hereditary nephropathy carrier dogs

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Alport syndrome and the X chromosome: implications of a diagnosis of Alport syndrome in females

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.223

7 January 2021

Identifiers

DOI

10.1038/KI.2009.223

1 reference

20 August 2017

1 reference